Bristol-Myers Squibb Co
BMY55.300USD
-1.890-3.30%
收盘 04/04, 16:00（美东）报价延迟15分钟
110.93B总市值
亏损市盈率 TTM
关于 Bristol-Myers Squibb Co 公司
百时美施贵宝公司是一家生物制药公司，致力于发现、开发和提供先进药物，帮助患者战胜严重疾病。该公司提供各种治疗类别的产品，包括肿瘤学、血液学、免疫学、心血管和神经科学。其医药产品包括化学合成或小分子药物、通过生物过程产生的产品（称为生物制剂）和嵌合抗原受体 (CAR-T) 细胞疗法。小分子药物通常以片剂或胶囊的形式口服，但也使用其他药物输送机制。生物制剂通过注射或静脉输液给患者给药。其在线产品包括 Eliquis、Opdivo、Orencia、Pomalyst/Imnovid、Yervoy、Sprycel、Reblozyl、Opdualag、Abecma、Zeposia 等。该公司的产品线包括 Krazati、MRTX1719、RYZ101、KarXT、ORM-6151 和 Repotrectinib。
公司简介
公司代码BMY
公司名称Bristol-Myers Squibb Co
上市日期Jul 05, 1929
成立日期1933
CEODr. Christopher S. (Chris) Boerner, Ph.D.
员工数量34100
证券类型Ordinary Share
年结日Jul 05
公司地址Route 206 And Province Line Road
城市PRINCETON
上市交易所NYSE Consolidated
国家United States of America
邮编08543
电话16092524621
网址https://www.bms.com/in
公司代码BMY
上市日期Jul 05, 1929
成立日期1933
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Sandra Leung
Ms. Sandra Leung
Executive Vice President, General Counsel, Member of the Leadership Team
Executive Vice President, General Counsel, Member of the Leadership Team
465.37K
+3.85%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
79.26K
+23.98%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
14.97K
+27.27%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, Corporate Affairs, Member of the Leadership Team
Executive Vice President, Corporate Affairs, Member of the Leadership Team
8.32K
+65.81%
Mr. Robert Plenge, M.D., Ph.D.
Mr. Robert Plenge, M.D., Ph.D.
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Sandra Leung
Ms. Sandra Leung
Executive Vice President, General Counsel, Member of the Leadership Team
Executive Vice President, General Counsel, Member of the Leadership Team
465.37K
+3.85%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
79.26K
+23.98%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
14.97K
+27.27%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
收入明细
单位: USD更新时间: 5 小时前
单位: USD更新时间: 5 小时前
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
地区USD
名称
营收
占比
United States
34.10B
70.61%
International
13.20B
27.33%
other
996.00M
2.06%
业务
地区
业务USD
名称
营收
占比
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.29%
BlackRock Institutional Trust Company, N.A.
4.77%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.96%
Other
75.20%
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.29%
BlackRock Institutional Trust Company, N.A.
4.77%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.96%
Other
75.20%
股东类型
股东统计
占比
Investment Advisor
36.58%
Investment Advisor/Hedge Fund
32.53%
Research Firm
2.82%
Pension Fund
2.50%
Bank and Trust
2.24%
Sovereign Wealth Fund
1.85%
Hedge Fund
1.70%
Insurance Company
0.16%
Foundation
0.11%
Other
19.51%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
4165
1.65B
81.00%
+21.90M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
2022Q4
4105
1.66B
77.92%
-72.60M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
189.02M
9.29%
+1.40M
+0.75%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
97.01M
4.77%
-7.46M
-7.14%
Dec 31, 2024
State Street Global Advisors (US)
95.14M
4.68%
+2.25M
+2.42%
Dec 31, 2024
JP Morgan Asset Management
63.10M
3.1%
+12.35M
+24.34%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
60.30M
2.96%
-729.93K
-1.20%
Dec 31, 2024
Capital International Investors
45.87M
2.25%
+3.22M
+7.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
44.39M
2.18%
+1.19M
+2.75%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
28.50M
1.4%
+12.26M
+75.55%
Dec 31, 2024
Fidelity Management & Research Company LLC
27.55M
1.35%
-9.07M
-24.78%
Dec 31, 2024
查看更多
持股ETF
更新时间: 23 小时前
更新时间: 23 小时前
机构名称
占比
First Trust NASDAQ Pharmaceuticals ETF
10.07%
VanEck Morningstar Wide Moat Value ETF
5.06%
Invesco Pharmaceuticals ETF
5.02%
Global X US Cash Flow Kings 100 ETF
4.97%
Invesco S&P Ultra Dividend Revenue ETF
4.9%
VictoryShares Free Cash Flow ETF
4.81%
VanEck Pharmaceutical ETF
4.81%
Cullen Enhanced Equity Income ETF
4.53%
Tema Oncology ETF
4.47%
iShares U.S. Pharmaceuticals ETF
4.38%
查看更多
First Trust NASDAQ Pharmaceuticals ETF
占比10.07%
VanEck Morningstar Wide Moat Value ETF
占比5.06%
Invesco Pharmaceuticals ETF
占比5.02%
Global X US Cash Flow Kings 100 ETF
占比4.97%
Invesco S&P Ultra Dividend Revenue ETF
占比4.9%
VictoryShares Free Cash Flow ETF
占比4.81%
VanEck Pharmaceutical ETF
占比4.81%
Cullen Enhanced Equity Income ETF
占比4.53%
Tema Oncology ETF
占比4.47%
iShares U.S. Pharmaceuticals ETF
占比4.38%
分红派息
近5年累计派现
22.71B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据